Clinical significance of CYLD downregulation in breast cancer.
Hayashi M, Jono H, Shinriki S, Nakamura T, Guo J, Sueta A, Tomiguchi M, Fujiwara S, Yamamoto-Ibusuki M, Murakami K, Yamashita S, Yamamoto Y, Li JD, Iwase H, Ando Y.
Hayashi M, et al. Among authors: fujiwara s.
Breast Cancer Res Treat. 2014 Feb;143(3):447-57. doi: 10.1007/s10549-013-2824-3. Epub 2014 Jan 8.
Breast Cancer Res Treat. 2014.
PMID: 24398777